Toward a molecular microbial blood test for tuberculosis infection
Mycobacterium tuberculosis (Mtb) is a major human pathogen, responsible for an estimated 10.6 million cases of active tuberculosis (TB) and 1.3 million deaths worldwide in 2022 [1]. Most adult cases of active TB arise from the progression of asymptomatic Mtb infection, whose global prevalence has been estimated at 23% [2]. Risk of progression from infection to disease can be significantly reduced by administration of preventive antimicrobial therapy [3], and global roll-out of this intervention will be needed to achieve the World Health Organization (WHO) target of TB elimination by 2050 [4].
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Adrian R. Martineau, Shruthi Chandran, Winnie Palukani, Patricia Garrido, Jonathan Mayito, Stephen T. Reece, Divya Tiwari Tags: Perspective Source Type: research
More News: Antibiotic Therapy | Infectious Diseases | International Medicine & Public Health | Tuberculosis | WHO